Copyright
©The Author(s) 2017.
World J Gastroenterol. Apr 21, 2017; 23(15): 2763-2770
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2763
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2763
HBV | HCV | Non-viral | P value | |
Male (%) | 84.3 | 79.2 | 80.6 | < 0.250 |
Ethnicity (%) | ||||
Caucasian | 16.4 | 73.4 | 87.3 | < 0.001 |
Asian | 75.8 | 18.2 | 9.0 | < 0.001 |
Middle Eastern | 3.7 | 7.1 | 2.2 | < 0.001 |
Polynesian | 2.3 | 0.6 | 0.0 | < 0.001 |
Aboriginal | 0.3 | 0.2 | 1.1 | < 0.001 |
African | 1.3 | 0.4 | 0.4 | < 0.001 |
Median age (95%CI) | 57 (55-59) | 55 (54-56) | 64 (63-65) | < 0.001 |
Screening program (%) | 71 | 84 | 71 | < 0.001 |
Median AFP (95%CI) | 60 (40-98) | 21 (16-28) | 9 (6-19) | < 0.001 |
- Citation: Mohsen W, Rodov M, Prakoso E, Charlton B, Bowen DG, Koorey DJ, Shackel NA, McCaughan GW, Strasser SI. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World J Gastroenterol 2017; 23(15): 2763-2770
- URL: https://www.wjgnet.com/1007-9327/full/v23/i15/2763.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i15.2763